Psychedelic research and access in
Northern Mariana Islands
Federally, the usual psychedelic baseline still applies. At the Commonwealth level, CNMI law is straightforwardly prohibitionist for classical psychedelics: Schedule I includes ibogaine, LSD, mescaline, peyote, psilocin and psilocybin.
Key Insights
- 1
CNMI law still lists psilocybin and psilocin as Schedule I substances, alongside LSD, mescaline and ibogaine.
- 2
This source pass did not verify any territory-level psychedelic reform, regulated service pathway, or special access scheme.
- 3
The verified public health infrastructure is conventional: CHCC mental-health services, not psychedelic services.
- 4
CNMI should be treated as a low-visibility, low-implementation jurisdiction until stronger primary sources show otherwise.
Research Snapshot
Deep reportBlossom keeps Northern Mariana Islands as a state-level index, but no verified psychedelic clinical trials, stakeholders or events are linked to this jurisdiction yet.
Missing linked records are database coverage signals, not proof that no local policy discussion, care or informal activity exists.
- Active trials
- 0
- Total trials
- 0
- Stakeholders
- 0
- Events
- 0
Verified state-linked study sites
Linked trial records
0 physical, 0 jurisdiction-linked
Linked state-level events
Top Compounds
No compound signal is available from linked state trials yet.
Top Study Topics
No study-topic signal is available from linked state trials yet.
Access and Reimbursement
Ketamine/esketamine access; no state-regulated classical psychedelic pathwayThe verified public mental-health infrastructure I found is the Commonwealth Healthcare Corporation’s mental health services, which offer adult mental-health care, medication management, and related support. That is standard behavioural-health provision, not a psychedelic programme. This source pass did not verify a dedicated CNMI ketamine clinic, a public esketamine service line, or a territory-specific reimbursement pathway for psychedelic-adjacent care in the reviewed sources.
Research signal
AvailableThe reviewed sources surfaced public mental-health service provision rather than a distinct psychedelic research ecosystem. This source pass did not verify a CNMI university or hospital site running registered psilocybin, MDMA, ibogaine, or ketamine-for-psychiatry trials in this source pass.
Ketamine / esketamine
AvailableThe verified public mental-health infrastructure I found is the Commonwealth Healthcare Corporation’s mental health services, which offer adult mental-health care, medication management, and related support. That is standard behavioural-health provision, not a psychedelic programme.
No state service model
Not AvailableNo state-regulated psilocybin, MDMA or natural-medicine service model is verified for Northern Mariana Islands.
Classical psychedelics
Not AvailableThis source pass did not verify a recent CNMI psychedelic bill, advisory council, ballot measure, or implementation workstream. The territory’s law reviewed here still treats psilocin and psilocybin as Schedule I substances, and I found no primary-source evidence of deprioritisation or carve-outs for therapeutic use.
Reimbursement / payment
LimitedNo dedicated psychedelic reimbursement pathway is verified for Northern Mariana Islands; ordinary medical coverage rules may apply to ketamine or esketamine where available.
Policy and Access Timeline
State-level bills, laws, pilots, agency actions and reimbursement signals that shape real-world access.
21 Sept 2018
ActiveAgency GuidancePublic Law 20-66 amended the CNMI schedule provision, but the section still listed psil...
Public Law 20-66 amended the CNMI schedule provision, but the section still listed psilocin and psilocybin as Schedule I substances.
Northern Mariana IslandsCNMI § 2114→
Regulatory Status
Federally, the usual psychedelic baseline still applies. At the Commonwealth level, CNMI law is straightforwardly prohibitionist for classical psychedelics: Schedule I includes ibogaine, LSD, mescaline, peyote, psilocin and psilocybin. This source pass did not verify any territory-level psychedelic services programme, decriminalisation law, or special access pathway. The most important caution here is not to over-read the territory’s cannabis history into psychedelics. The same CNMI schedule provision that shows the 2018 amendment history still lists psilocin and psilocybin as Schedule I substances. On the evidence reviewed, CNMI remains a no-verified-pathway jurisdiction for psychedelic access outside conventional lawful research or ordinary medical ketamine/esketamine routes.
Medical Access Summary
The verified public mental-health infrastructure I found is the Commonwealth Healthcare Corporation’s mental health services, which offer adult mental-health care, medication management, and related support. That is standard behavioural-health provision, not a psychedelic programme.###
This source pass did not verify a dedicated CNMI ketamine clinic, a public esketamine service line, or a territory-specific reimbursement pathway for psychedelic-adjacent care in the reviewed sources. The safest summary is that any lawful ketamine or esketamine access would depend on ordinary clinician-led practice capacity, while psilocybin, MDMA and related compounds remain outside any verified territory-authorised care route.###
Policy and Access Context
This source pass did not verify a recent CNMI psychedelic bill, advisory council, ballot measure, or implementation workstream. The territory’s law reviewed here still treats psilocin and psilocybin as Schedule I substances, and I found no primary-source evidence of deprioritisation or carve-outs for therapeutic use.###
That means the practical policy context is one of baseline prohibition and limited visible institutional development. For Blossom’s page, the territory should be described as low-activity and low-visibility in psychedelic policy, with ordinary public mental-health services but no verified territory-specific psychedelic framework.###
Research Focus
The reviewed sources surfaced public mental-health service provision rather than a distinct psychedelic research ecosystem. This source pass did not verify a CNMI university or hospital site running registered psilocybin, MDMA, ibogaine, or ketamine-for-psychiatry trials in this source pass.###
Accordingly, the territory should not be presented as a research hub. If a local research signal exists, it was not visible in the primary and near-primary materials reviewed here, and that uncertainty should be preserved rather than filled with inference.###
Implementation Context
There is no verified territory implementation machinery for psychedelic services: no licensing office, advisory board, facilitator framework, service-centre rules, or product-testing regime surfaced in the sources reviewed. The operative implementation machinery remains the criminal law and ordinary health-service delivery system.###
From a practical access perspective, that means there is nothing comparable to Oregon’s roll-out. Any future movement would likely need overt legislative action or a visible public-health or hospital-led programme, neither of which I verified here.###
Ecosystem Context
The only clearly verifiable public ecosystem node I found was CHCC’s mental-health service structure. This source pass did not verify a dedicated psychedelic clinic network, a known territory advocacy coalition, or a conference/expo footprint focused on psychedelics in CNMI.###
For this page, restraint matters: CNMI looks more like a jurisdiction where ordinary behavioural-health capacity exists but the documented psychedelic ecosystem is minimal or opaque.###
Key Milestones
Future Outlook
Over the next 12 to 24 months, the most likely near-term scenario is continuity rather than reform. Unless a bill, executive initiative, or hospital-led programme emerges, CNMI is unlikely to become a meaningful access or implementation jurisdiction in Blossom’s taxonomy.###
What matters most to watch is not consumer activity but institutional visibility: any new CNMI legislation, any CHCC or private-sector announcement on ketamine/esketamine capacity, and any published clinical-trial listing tied to Saipan, Tinian or Rota. Until then, access remains conventional and limited.###
Sources and Verification
Last updated 18 May 2026. Source links are drawn from citation annotations in the subnational report.